Access the full text.
Sign up today, get DeepDyve free for 14 days.
N. Sueoka-Aragane, K. Imai, K. Komiya, A. Sato, R. Tomimasu, Takashi Hisatomi, T. Sakuragi, M. Mitsuoka, S. Hayashi, K. Nakachi, E. Sueoka (2008)
Exon 19 of EGFR mutation in relation to the CA‐repeat polymorphism in intron 1Cancer Science, 99
S. Saito, S. Ota, E. Yamada, H. Inoko, M. Ota (2000)
Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population.Tissue antigens, 56 6
Takashi Fukuyama, T. Hanagiri, M. Takenoyama, Y. Ichiki, M. Mizukami, T. So, M. Sugaya, T. So, K. Sugio, K. Yasumoto (2006)
Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma.Cancer research, 66 9
Florence Calvez, A. Mukeria, J. Hunt, Olaf Kelm, R. Hung, P. Tanière, P. Brennan, P. Boffetta, D. Zaridze, P. Hainaut (2005)
TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers.Cancer research, 65 12
M. Janssen‐Heijnen, J. Coebergh (2001)
Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe.Lung cancer, 31 2-3
M. Torres, M. Moraes (2011)
Nomenclature for factors of the HLA system.Bulletin of the World Health Organization, 52 3
S. Marsh, E. Albert, W. Bodmer, R. Bontrop, B. Dupont, H. Erlich, D. Geraghty, J. Hansen, C. Hurley, B. Mach, W. Mayr, P. Parham, E. Petersdorf, T. Sasazuki, G. Schreuder, J. Strominger, A. Svejgaard, P. Terasaki, J. Trowsdale (2005)
Nomenclature for factors of the HLA system, 2004International Journal of Immunogenetics, 32
K. Matsuo, A. Hiraki, Hidemi Ito, T. Kosaka, Takeshi Suzuki, K. Hirose, K. Wakai, Y. Yatabe, T. Mitsudomi, K. Tajima (2008)
Soy consumption reduces the risk of non‐small‐cell lung cancers with epidermal growth factor receptor mutations among JapaneseCancer Science, 99
C. Mountain (2000)
The international system for staging lung cancer.Seminars in surgical oncology, 18 2
A. Gazdar (2009)
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsOncogene, 28
H. Uramoto, K. Sugio, T. Oyama, K. Ono, M. Sugaya, T. Yoshimatsu, T. Hanagiri, M. Morita, K. Yasumoto (2006)
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.Lung cancer, 51 1
T. Baba, T. Hanagiri, Y. Ichiki, K. Kuroda, Y. Shigematsu, M. Mizukami, M. Sugaya, M. Takenoyama, K. Sugio, K. Yasumoto (2007)
Lack and restoration of sensitivity of lung cancer cells to cellular attack with special reference to expression of human leukocyte antigen class I and/or major histocompatibility complex class I chain related molecules A/BCancer Science, 98
K. Matsuo, Hidemi Ito, Y. Yatabe, A. Hiraki, K. Hirose, K. Wakai, T. Kosaka, Takeshi Suzuki, K. Tajima, T. Mitsudomi (2007)
Risk factors differ for non‐small‐cell lung cancers with and without EGFR mutation: assessment of smoking and sex by a case‐control study in JapaneseCancer Science, 98
市来 嘉伸 (2006)
Simultaneous cellular and humoral immune response against mutated p53 in a patient with lung cancer(第23回産業医科大学学会総会学術講演会記録), 28
T. Ludwig, P. Fisher, S. Ganesan, A. Efstratiadis (2001)
Tumorigenesis in mice carrying a truncating Brca1 mutation.Genes & development, 15 10
N. Nose, K. Sugio, T. Oyama, T. Nozoe, H. Uramoto, T. Iwata, T. Onitsuka, K. Yasumoto (2009)
Association between estrogen receptor-beta expression and epidermal growth factor receptor mutation in the postoperative prognosis of adenocarcinoma of the lung.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 3
E. Wei, Amal Anga, Sherry Martin, Joyce Jackson, M. Nordberg, G. Herrera, E. Turbat-Herrera (2007)
EGFR expression as an ancillary tool for diagnosing lung cancer in cytology specimensModern Pathology, 20
Shiu-Feng Huang, Hui-ping Liu, Ling-Hui Li, Yuan-Chieh Ku, Yu-Ning Fu, Hsien‐Yu Tsai, Ya-Ting Chen, Yung-feng Lin, W. Chang, H. Kuo, Yi-cheng Wu, Yi-Rong Chen, S. Tsai (2004)
High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in TaiwanClinical Cancer Research, 10
O. Mandelboim, Hugh Reyburn, M. Valés-Gómez, Laszlo Pazmany, Marco Colonna, Giovanna Borsellino, J. Strominger (1996)
Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex moleculesThe Journal of Experimental Medicine, 184
Ziqiang Yuan, Joongho Shin, Andrew Wilson, S. Goel, Y. Ling, Naseem Ahmed, Higinio Dopeso, M. Jhawer, Shannon Nasser, C. Montagna, K. Fordyce, L. Augenlicht, L. Aaltonen, D. Arango, T. Weber, J. Mariadason (2009)
An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression.Cancer research, 69 19
Marsh (2005)
Nomenclature for factors of the HLA system, 2004Tissue Antigens, 65
F. Hirsch, M. Varella-Garcia, P. Bunn, Michael Maria, R. Veve, Roy Bremmes, A. Baron, C. Zeng, W. Franklin (2003)
Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 20
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
H. Suzuki, Takashi Takahashi, T. Kuroishi, M. Suyama, Y. Ariyoshi, Toshitada Takahashi, R. Ueda (1992)
p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking.Cancer research, 52 3
E. Thorsby, B. Lie (2005)
HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms.Transplant immunology, 14 3-4
J. Marks, B. Golas, Tomas Kirchoff, V. Miller, Gregory Riely, K. Offit, W. Pao (2008)
EGFR mutant lung adenocarcinomas in patients with germline BRCA mutations.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 3 7
H. Buerger, J. Packeisen, A. Boecker, N. Tidow, C. Kersting, K. Bielawski, J. Isola, Y. Yatabe, K. Nakachi, W. Boecker, B. Brandt (2004)
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence—first results of an inter‐ethnic breast cancer studyThe Journal of Pathology, 203
M. Wong, W. Lam, E. Wang, S. Chiu, C. Lam, L. Chung (2002)
Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance.Cancer research, 62 15
T. Mitsudomi, T. Kosaka, H. Endoh, Y. Horio, T. Hida, S. Mori, S. Hatooka, M. Shinoda, Takashi Takahashi, Y. Yatabe (2005)
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 11
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
M. Sugaya, M. Takenoyama, Y. Shigematsu, T. Baba, Takashi Fukuyama, Y. Nagata, M. Mizukami, T. So, Y. Ichiki, M. Yasuda, T. So, T. Hanagiri, K. Sugio, K. Yasumoto (2006)
Identification of HLA‐A24 restricted shared antigen recognized by autologous cytotoxic T lymphocytes from a patient with large cell carcinoma of the lungInternational Journal of Cancer, 120
J. Paez, P. Jänne, Jeffrey Lee, Sean Tracy, H. Greulich, S. Gabriel, P. Herman, F. Kaye, N. Lindeman, T. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M. Eck, W. Sellers, B. Johnson, M. Meyerson (2004)
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 304
J. Ellis, Valerie Henson, Valerie Henson, R. Slack, Jennifer Ng, R. Hartzman, Carolyn Hurley (2000)
Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231.Human immunology, 61 3
K. Sugio, H. Uramoto, K. Ono, T. Oyama, T. Hanagiri, M. Sugaya, Y. Ichiki, T. So, S. Nakata, Masaru Morita, K. Yasumoto (2006)
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smokingBritish Journal of Cancer, 94
T. So, M. Takenoyama, M. Mizukami, Y. Ichiki, M. Sugaya, T. Hanagiri, K. Sugio, K. Yasumoto (2005)
Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.Cancer research, 65 13
Y. Ko, L. Cheng, Chien-Hung Lee, Jhi-Jhu Huang, Ming-Shyan Huang, E. Kao, Hwei‐Zu Wang, Hsiang-Ju Lin (2000)
Chinese food cooking and lung cancer in women nonsmokers.American journal of epidemiology, 151 2
E. Steels, M. Paesmans, T. Berghmans, F. Branle, F. Lemaitre, C. Mascaux, A. Meert, F. Vallot, J. Lafitte, J. Sculier (2001)
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis.The European respiratory journal, 18 4
T. So, M. Takenoyama, M. Sugaya, M. Yasuda, R. Eifuku, T. Yoshimatsu, Toshihiro Osaki, K. Yasumoto (2001)
Unfavorable prognosis of patients with non-small cell lung carcinoma associated with HLA-A2.Lung cancer, 32 1
P. Terasaki, J. McClelland (1964)
Microdroplet Assay of Human Serum CytotoxinsNature, 204
T. Lynch, D. Bell, Raffaella Sordella, S. Gurubhagavatula, R. Okimoto, Brian Brannigan, Patricia Harris, Sara Haserlat, J. Supko, F. Haluska, D. Louis, D. Christiani, J. Settleman, D. Haber (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.The New England journal of medicine, 350 21
Ya‐Wen Cheng, H. Chiou, G. Sheu, L. Hsieh, Jung‐Ta Chen, Chih‐Yi Chen, J-M. Su, Hue Lee (2001)
The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women.Cancer research, 61 7
Y. Nagata, T. Hanagiri, M. Takenoyama, Takashi Fukuyama, M. Mizukami, T. So, Y. Ichiki, M. Sugaya, K. Sugio, K. Yasumoto (2005)
Identification of the HLA-Cw*0702-Restricted Tumor-Associated Antigen Recognized by a CTL Clone from a Lung Cancer PatientClinical Cancer Research, 11
Y. Nagata, T. Hanagiri, M. Mizukami, K. Kuroda, Y. Shigematsu, T. Baba, Y. Ichiki, M. Yasuda, T. So, M. Takenoyama, K. Sugio, A. Nagashima, K. Yasumoto (2009)
Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan.Lung cancer, 65 1
K. Cao, J. Hollenbach, Xuejiang Shi, Wenxia Shi, M. Chopek, M. Fernández-Viña, M. Fernández-Viña (2001)
Analysis of the frequencies of HLA-A, B, and C alleles and haplotypes in the five major ethnic groups of the United States reveals high levels of diversity in these loci and contrasting distribution patterns in these populations.Human immunology, 62 9
H. Asamura, T. Goya, Y. Koshiishi, Y. Sohara, K. Eguchi, M. Mori, Y. Nakanishi, R. Tsuchiya, K. Shimokata, H. Inoue, T. Nukiwa, Etsuo Miyaoka (2008)
A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung CancersJournal of Thoracic Oncology, 3
T. Shimura, M. Hagihara, K. Takebe, B. Munkhbat, T. Odaka, H. Kato, Y. Nagamachi, Kimiyoshi Tsuji (1994)
The study of tumor necrosis factor beta gene polymorphism in lung cancer patientsCancer, 73
M. Takenoyama, J. Baurain, M. Yasuda, T. So, M. Sugaya, T. Hanagiri, K. Sugio, K. Yasumoto, T. Boon, P. Coulie (2006)
A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinomaInternational Journal of Cancer, 118
W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, I. Sarkaria, Bhuvanesh Singh, R. Heelan, V. Rusch, L. Fulton, E. Mardis, Doris Kupfer, R. Wilson, M. Kris, H. Varmus (2004)
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.Proceedings of the National Academy of Sciences of the United States of America, 101 36
J. Minna, J. Roth, A. Gazdar (2002)
Focus on lung cancer.Cancer cell, 1 1
B. Modrek, Lin Ge, A. Pandita, Eva Lin, S. Mohan, Peng Yue, Steve Guerrero, William Lin, Thinh Pham, Z. Modrušan, S. Seshagiri, H. Stern, P. Waring, L. Garraway, J. Chant, D. Stokoe, G. Cavet (2009)
Oncogenic Activating Mutations Are Associated with Local Copy GainMolecular Cancer Research, 7
S. Ahrendt, P. Decker, Enas Alawi, Yong‐ran Zhu, M. Sanchez-Cespedes, Stephen Yang, G. Haasler, A. Kajdacsy‐Balla, M. Demeure, D. Sidransky (2001)
Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lungCancer, 92
ORIGINAL ARTICLE Correlation Between HLA Alleles and EGFR Mutation in Japanese Patients with Adenocarcinoma of the Lung Hidetaka Uramoto, PhD, MD, Tomoko So, PhD, MD, Yoshika Nagata, PhD, MD, Koji Kuroda, PhD, MD, Yoshiki Shigematsu, PhD, MD, Tetsuro Baba, PhD, MD, Tetsuya So, PhD, MD, Mitsuhiro Takenoyama, PhD, MD, Takeshi Hanagiri, PhD, MD, and Kosei Yasumoto, PhD, MD ung cancer is the most common cause of cancer death in Introduction: The identification of activating mutations in the Lthe majority of developed countries. The absolute number epidermal growth factor receptor (EGFR) gene is one of the most of patients with lung cancer is still increasing worldwide. intriguing recent discoveries in the field of lung cancer research, and Despite advances in therapeutic modalities, the prognosis of they are more commonly found in adenocarcinoma occurring in 3,4 lung cancer is poor. In particular, the patients with ad- females, never/light smokers, and East Asian patients. Why such vanced-stage disease experienced a high mortality rate de- certain patients are susceptible to the development of EGFR-mutant 4 spite multidisciplinary treatment. Therefore, the develop- tumors is currently unknown. ment of new modalities such as molecular target therapy is Methods: This study evaluated the medical records of
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Aug 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.